Erika Carmel-Tech Ltd (ERKA) Fair Value & Analysis
Healthcare · Il · Market cap 22.2M ILA
Fair value as of: Jun 24, 2026
Analysis
Erika Carmel-Tech Ltd (ERKA) currently trades at 0.5280 ILA, while our model-based Fair Value estimate is 0.7000 ILA — implying the stock looks roughly 32.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Erika Carmel-Tech Ltd develops, manufactures, markets, distributes, and sells the B-Cure laser products in Israel and internationally. It provides B-Cure Laser Classic, a non-invasive and safe medical device for the treatment of chronic and acute pain for home use; and B-Cure Laser Pro, a clinically proven, non-invasive and safe medical device for treatment of both acute and chronic conditions. The company treats achilles tendon inflammation, burns, carpal tunnel syndrome, finger joint pain, fibromyalgia, hip pain, post-dental treatment, lower back pain, neck pain, shoulder pain, knee pain, tennis elbow, toe joint pain, temporomandibular joint disorders, upper back pain, and wounds. The company was formerly known as Erika B-Cure Laser Ltd and changed its name to Erika Carmel-Tech Ltd in October 2025. Erika Carmel-Tech Ltd was incorporated in 2007 and is headquartered in Haifa, Israel.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Erika Carmel-Tech Ltd (ERKA) undervalued?
What is the fair value of ERKA?
What is the quality score of ERKA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.